Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.59 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5990290 | 0.90 | MAP2K1 (0.56) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL5990941 | 0.89 | MAP2K1 (0.61) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL6826546 | 0.86 | MAP2K1 (0.74) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL5990429 | 0.85 | MAP2K1 (0.62) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL14219706 | 0.81 | MAP2K1 (0.57) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL5989971 | 0.80 | MAP2K1 (0.48) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL6829209 | 0.78 | MAP2K1 (0.75) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL6830448 | 0.78 | MAP2K1 (0.74) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL6831518 | 0.77 | MAP2K1 (0.70) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 | |
| SCHEMBL6826762 | 0.77 | MAP2K1 (0.77) | MAP2K1MAP2K2PIM1CAMK2BHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467965-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | Warner-Lambert Company LLC (US) | 2004-10-20 | — | — | EP | claimed |
| US-6770778-B2 | MAP KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; RESTENOSIS, PSORIASIS, AND ATHEROSCLEROSIS TREATMENT; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | PFIZER INC | 2004-08-03 | — | — | US | claimed |
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | WARNET-LAMBERT COMPANY LLC | 2003-12-18 | — | — | US | claimed |
| WO-2003062189-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | claimed |
| US-7078438-B2 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050137263-A1 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY, LLC | 2005-06-23 | — | — | US | disclosed |
| US-6891066-B2 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1467965-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | Warner-Lambert Company LLC (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1467968-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | Warner-Lambert Company LLC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6770778-B2 | MAP KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; RESTENOSIS, PSORIASIS, AND ATHEROSCLEROSIS TREATMENT; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | PFIZER INC | 2004-08-03 | — | — | US | disclosed |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | REWCASTLE GORDON WILLIAM (NZ) | 2004-01-08 | — | — | US | disclosed |
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | WARNET-LAMBERT COMPANY LLC | 2003-12-18 | — | — | US | disclosed |
| WO-2003062191-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062189-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | AADAC, EGLN3, HCAR2 | MAP2K1 4732/4885MAP2K2 4641/4885PIM1 4360/4885 |
| US-20050137263-A1 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | PAH, EGLN3, PAOX | MAP2K1 4555/4885MAP2K2 4495/4885PIM1 4241/4885 |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | HCAR2, EGLN3, AADAC | MAP2K1 4692/4885MAP2K2 4611/4885PIM1 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.